- Trial phase
- Approved (10 mg/mL); Research/Preclinical (4% formulation)
- Time to market
- The standard 10 mg/mL formulation is already on the market. The 4% concentrated formulation appears to be an experimental/research-stage product with no publicly disclosed regulatory submission or commercialization timeline.
- Why 3/10
- No hard dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for the 4% formulation in the next 12 months. The standard 10 mg/mL product is already approved and commercialized. Alfaxan is one small product within Zoetis's massive diversified portfolio (~$9.5B revenue), so even a label expansion would have negligible impact on ZTS shares.
Alfaxan Multidose 4% has no scheduled regulatory decision or pivotal readout in the next 12 months. The standard 10 mg/mL formulation is already marketed. Watch for any FDA submission or label expansion for the 4% concentrated formulation, but none is currently visible. Zoetis's stock moves on company-wide earnings and its large dermatology/parasiticide portfolio, not on this single anesthetic product.
Price Chart
Executive Summary
Alfaxan Multidose 4% is a concentrated (40 mg/mL, 4% w/v) experimental formulation of alfaxalone, a neuroactive steroid injectable anesthetic for veterinary use. The standard Alfaxan Multidose (10 mg/mL) is FDA-approved for dogs and cats (NADA 141-342, originally 2012, multidose version approved June 2018) and indexed for minor species (Alfaxan Multidose IDX, February 2020). The 4% formulation (development code RD0387) was developed by Jurox, which Zoetis acquired in 2022, and has been studied in research settings for intramuscular sedation in dogs and wildlife immobilization, but it does not appear to have a separate FDA approval or commercial launch in the US. For Zoetis (NYSE: ZTS), a $9.5B+ revenue animal health giant, Alfaxan is a modest product within a vast portfolio and the 4% variant is a niche R&D project with no near-term binary catalyst.
How It Works
Alfaxalone is a synthetic steroid that binds to GABA-A receptors in the brain and spinal cord, enhancing the effect of the body's natural calming signals. This produces general anesthesia (loss of consciousness) and sedation. It is injected intravenously or intramuscularly to sedate or anesthetize animals for veterinary procedures.
Trial Status
The standard Alfaxan Multidose (10 mg/mL) is FDA-approved and commercially marketed for dogs and cats. The Alfaxan Multidose IDX variant is indexed for minor species (exotic animals, birds, reptiles, fish, etc.). The 4% (40 mg/mL) concentrated formulation (RD0387) has been evaluated in published research studies for intramuscular sedation in dogs and wildlife immobilization but has not progressed to a registrational clinical trial or FDA submission visible in public sources.
The Two-Sided Case
Upcoming Catalysts
- No scheduled regulatory or clinical catalysts identified for the 4% formulation
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Zoetis Inc. 8-K ZTS ·Originating report